Peptide of the Week: Epitalon — 10% Off This Week
Peptide of the Week: Epitalon — 10% Off This Week
Ipamorelin is a synthetic pentapeptide studied as a selective growth hormone secretagogue and ghrelin receptor agonist. In research settings, it is primarily examined for its ability to stimulate growth hormone release through GHSR-related signaling pathways while showing a different endocrine selectivity profile than some earlier compounds in the same category. Source: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin and https://pubmed.ncbi.nlm.nih.gov/9849822/
Ipamorelin is a synthetic research peptide commonly grouped with growth hormone secretagogues. It is studied for its ability to activate the growth hormone secretagogue receptor, also referred to as the ghrelin receptor, and stimulate growth hormone release from the pituitary. Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin and https://pubmed.ncbi.nlm.nih.gov/9849822/
From a research perspective, Ipamorelin is most relevant as a signaling compound used to investigate GH-axis biology, endocrine selectivity, and downstream physiological pathways linked to growth hormone release. Sources: https://pubmed.ncbi.nlm.nih.gov/9849822/ and https://pubmed.ncbi.nlm.nih.gov/10496658/
In simple terms, Ipamorelin is studied as a peptide that can signal the body to release growth hormone through the ghrelin receptor pathway. It is not growth hormone itself. Researchers are mainly interested in it because early studies suggested a relatively selective GH-releasing profile, but the human evidence base is still limited and much of the published work remains preclinical.
Ipamorelin is studied as a ghrelin mimetic. Ghrelin is a signaling molecule associated with appetite, gastrointestinal motility, and growth hormone release. Ipamorelin binds to the ghrelin receptor pathway and is studied for whether it can trigger GH secretion in a targeted way.
One of the reasons Ipamorelin attracted interest in the literature is that early pharmacology work suggested a more selective hormonal profile than some older secretagogues, especially regarding ACTH and cortisol release in the tested models.
Growth hormone secretagogues are often studied as tools for understanding endocrine signaling rather than as broad outcome compounds. In the case of Ipamorelin, the strongest published rationale centers on GH release, ghrelin receptor activity, and specific downstream physiologic effects that can be measured in laboratory settings.
To understand the efficacy of Ipamorelin, it must be compared against other common GH-releasing agents. Ipamorelin is unique because it lacks the “acidic” side-effect profile of its predecessors.
Research into Ipamorelin focuses on its ability to mimic the natural pulsatile nature of GH secretion. Because it does not cause a massive “dump” of growth hormone, but rather enhances the natural pulses, it is often studied for its role in maintaining long-term endocrine health.
Selective Pituitary Activation: Ipamorelin binds to the GHS-R1a receptor. Unlike GHRP-2, it does not activate the receptors responsible for releasing ACTH or Prolactin, making it a “clean” secretagogue.
Metabolic Signaling: Research indicates that Ipamorelin may increase IGF-1 (Insulin-like Growth Factor 1) levels, which is a primary mediator of the effects of growth hormone on tissue growth and repair.
Gastric Motility: Some studies have explored Ipamorelin’s potential in treating postoperative ileus due to its interaction with ghrelin receptors in the digestive tract.
At Luxara Labs, we ensure that every batch of Ipamorelin meets the rigorous standards required for peer-reviewed research. We provide the purest 3rd-party tested peptides available in North America.
Chemical Formula:
Molecular Weight: g/mol
Purity Level: ≥99% (HPLC Verified)
Shipping: Expedited shipping is available across all of Canada and the USA.
The primary research use case for Ipamorelin is straightforward: it is studied for its ability to stimulate growth hormone release and to help researchers better understand secretagogue-driven GH signaling.
Human research has examined how Ipamorelin behaves in the body and how GH levels respond at different infusion rates. This PK/PD work is important because it provides controlled human data, even though it does not by itself establish broad real-world outcome claims.
Some of the more clinically visible literature on Ipamorelin has focused on gastrointestinal motility and postoperative ileus. Animal studies and a phase 2 proof-of-concept human trial explored whether ghrelin receptor agonism could improve postoperative gut function.
Preclinical studies have also explored Ipamorelin in relation to bone formation, bone mineral content, and longitudinal growth-related physiology in animal models. These findings are mechanistically interesting, but they remain preclinical and should not be overstated.
The clearest takeaway from the literature is that Ipamorelin has a legitimate scientific basis as a ghrelin-receptor-linked GH secretagogue. That part is supported by early pharmacology work, PK/PD studies, and later exploratory research.
At the same time, the evidence base is not broad enough to justify many of the aggressive claims often made online. Most of the literature is either mechanistic, preclinical, or limited-scope human research.
Simple analogy: Ipamorelin is better understood as a signal trigger rather than a replacement hormone. It does not act as growth hormone itself. Instead, it is studied for whether it can activate a receptor pathway that prompts GH release.
What the evidence supports: Ipamorelin is a real, published research compound with a plausible mechanism involving ghrelin receptor activation and growth hormone release.
What the evidence does not support clearly: broad, high-certainty human outcome claims across recovery, body composition, anti-aging, or performance contexts. The currently available literature does not justify treating those claims as established facts.
No. FDA briefing materials state that there are no FDA-approved drug products containing Ipamorelin.
At Luxara Labs, Ipamorelin is positioned strictly as a research-use-only peptide for laboratory, analytical, and investigational contexts. For compounds in this category, the most important quality markers are identity, purity, storage discipline, and transparent documentation.
Researchers comparing peptide suppliers generally look for:
Ipamorelin is a synthetic pentapeptide studied as a selective growth hormone secretagogue and ghrelin receptor agonist. Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin and https://pubmed.ncbi.nlm.nih.gov/9849822/
It is studied for its ability to activate ghrelin receptor signaling and stimulate the release of growth hormone from the pituitary. Source: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin
No. Ipamorelin is not growth hormone itself. It is studied as a signaling peptide that may prompt GH release indirectly through receptor activation. Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipamorelin and https://pubmed.ncbi.nlm.nih.gov/9849822/
Published studies have explored GH signaling, endocrine selectivity, pharmacokinetics, gastrointestinal motility, postoperative ileus, and bone-related physiology. Sources: https://pubmed.ncbi.nlm.nih.gov/10496658/, https://pubmed.ncbi.nlm.nih.gov/25331030/, https://pubmed.ncbi.nlm.nih.gov/19289567/, and https://pubmed.ncbi.nlm.nih.gov/11735244/
No. FDA briefing materials state there are no FDA-approved drug products containing Ipamorelin. Source: https://www.fda.gov/media/182088/download
A large portion of the published literature is preclinical, with a smaller amount of human PK/PD and GI-focused clinical research. Sources: https://pubmed.ncbi.nlm.nih.gov/10496658/, https://pubmed.ncbi.nlm.nih.gov/11735244/, and https://pubmed.ncbi.nlm.nih.gov/25331030/
Because peptide identity, purity, handling, and documentation matter, especially where formal regulatory approval is absent and FDA materials have raised safety and characterization concerns. Sources: https://www.fda.gov/media/182088/download and https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Join our list and get an instant 10% discount code — valid for first-time buyers.
